Stock Groups

Aridis Pharmaceuticals Surges as Antibody Cocktail Works Against Omicron -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — Aridis Pharmaceuticals Inc (NASDAQ:) shares have rallied Tuesday morning. This is due to the news that AR-701, the antibody cocktail of AR Pharmaceuticals, is now effective against Omicron as well as other Covid-19 variants.

Aridis stock shares increased by 24% premarket. This is a good sign for an organization that has seen its stock drop throughout 2021. They trade 34% higher than Monday’s closing price.

AR-703 is able to bind to Omicron variants “with no loss of affinity” when compared to the Covid-19 strain. Aridis tests also revealed that AR-701 was neutralized against all the tested variants.

Vu Truong CEO at Aridis Pharmaceuticals stated that Omicron rendered the current COVID-19 vaccinations and monoclonal antibody substantially less efficacious. It is likely that future COVID19 variants will follow this trend. 

Addition: “Our laboratory results suggest that AR-701 could be a future-proof COVID-19 treatment that can protect against SARS-CoV-2 and SARS pandemics.”

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]